MorphoSys Chooses Incyte As Its Global Tafasitamab Partner

Analysts Cheer MorphoSys’s Choice Of Commercial Ally And Deal’s Terms

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

MorphoSys has chosen Incyte as its global partner for commercializing and further developing its lead asset, the Fc-engineered antibody tafasitamab that targets CD19.

Partnership
Duo Will Jointly Develop MorphoSys’s CD19 Targeting Antibody • Source: Shutterstock

In a pact widely welcomed by investors, MorphoSys AG and Incyte Corp. have inked a global collaboration and license pact to further develop and commercialize MorphoSys's anti-CD19 antibody tafasitamab, formerly known as MOR208, which is in clinical development for the treatment of B-cell malignancies such as diffuse large B-cell lymphoma and chronic lymphocytic leukemia.

The alliance was announced on 13 January and provides MorphoSys a partner with considerable experience in hematology and oncology. Incyte...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains